PURPOSE: A new PET ligand, 3-fluoro-5-(2-(2-(18)F-(fluoromethyl)-thiazol-4-yl)ethynyl)benzonitrile ((18)F-SP203), is a positron emission tomographic radioligand selective for metabotropic glutamate subtype 5 receptors. The purposes of this study were to estimate the radiation-absorbed doses of (18)F-SP203 in humans and to determine from the distribution of radioactivity in bone structures with various proportions of bone and red marrow whether (18)F-SP203 undergoes defluorination. METHODS: Whole-body images were acquired for 5 h after injecting (18)F-SP203 in seven healthy humans. Urine was collected at various time points. Radiation-absorbed doses were estimated by the Medical Internal Radiation Dose scheme. RESULTS: After injecting (18)F-SP203, the two organs with highest radiation exposure were urinary bladder wall and gallbladder wall, consistent with both urinary and fecal excretion. In the skeleton, most of the radioactivity was in bone structures that contain red marrow and not in those without red marrow. Although the dose to red marrow (30.9 microSv/MBq) was unusually high, the effective dose (17.8 microSv/MBq) of (18)F-SP203 was typical of that of other (18)F radiotracers. CONCLUSION: (18)F-SP203 causes an effective dose in humans typical of several other (18)F radioligands and undergoes little defluorination.
PURPOSE: A new PET ligand, 3-fluoro-5-(2-(2-(18)F-(fluoromethyl)-thiazol-4-yl)ethynyl)benzonitrile ((18)F-SP203), is a positron emission tomographic radioligand selective for metabotropic glutamate subtype 5 receptors. The purposes of this study were to estimate the radiation-absorbed doses of (18)F-SP203 in humans and to determine from the distribution of radioactivity in bone structures with various proportions of bone and red marrow whether (18)F-SP203 undergoes defluorination. METHODS: Whole-body images were acquired for 5 h after injecting (18)F-SP203 in seven healthy humans. Urine was collected at various time points. Radiation-absorbed doses were estimated by the Medical Internal Radiation Dose scheme. RESULTS: After injecting (18)F-SP203, the two organs with highest radiation exposure were urinary bladder wall and gallbladder wall, consistent with both urinary and fecal excretion. In the skeleton, most of the radioactivity was in bone structures that contain red marrow and not in those without red marrow. Although the dose to red marrow (30.9 microSv/MBq) was unusually high, the effective dose (17.8 microSv/MBq) of (18)F-SP203 was typical of that of other (18)F radiotracers. CONCLUSION: (18)F-SP203 causes an effective dose in humans typical of several other (18)F radioligands and undergoes little defluorination.
Authors: David R Sprague; Frederick T Chin; Jeih-San Liow; Masahiro Fujita; H Donald Burns; Richard Hargreaves; James B Stubbs; Victor W Pike; Robert B Innis; P David Mozley Journal: J Nucl Med Date: 2007-01 Impact factor: 10.057
Authors: Fabrice G Siméon; Amira K Brown; Sami S Zoghbi; Velvet M Patterson; Robert B Innis; Victor W Pike Journal: J Med Chem Date: 2007-06-16 Impact factor: 7.446
Authors: H Umesha Shetty; Sami S Zoghbi; Fabrice G Siméon; Jeih-San Liow; Amira K Brown; Pavitra Kannan; Robert B Innis; Victor W Pike Journal: J Pharmacol Exp Ther Date: 2008-09-19 Impact factor: 4.030
Authors: Terence G Hamill; Stephen Krause; Christine Ryan; Celine Bonnefous; Steve Govek; T Jon Seiders; Nicholas D P Cosford; Jeffrey Roppe; Ted Kamenecka; Shil Patel; Raymond E Gibson; Sandra Sanabria; Kerry Riffel; Waisi Eng; Christopher King; Xiaoqing Yang; Mitchell D Green; Stacey S O'Malley; Richard Hargreaves; H Donald Burns Journal: Synapse Date: 2005-06-15 Impact factor: 2.562
Authors: Simon M Ametamey; Lea J Kessler; Michael Honer; Matthias T Wyss; Alfred Buck; Samuel Hintermann; Yves P Auberson; Fabrizio Gasparini; Pius A Schubiger Journal: J Nucl Med Date: 2006-04 Impact factor: 10.057
Authors: Simon M Ametamey; Valerie Treyer; Johannes Streffer; Matthias T Wyss; Mark Schmidt; Milen Blagoev; Samuel Hintermann; Yves Auberson; Fabrizio Gasparini; Uta C Fischer; Alfred Buck Journal: J Nucl Med Date: 2007-02 Impact factor: 10.057
Authors: Yong Hoon Ryu; Jeih-San Liow; Sami Zoghbi; Masahiro Fujita; Jerry Collins; Dnyanesh Tipre; Janet Sangare; Jinsoo Hong; Victor W Pike; Robert B Innis Journal: J Nucl Med Date: 2007-06-15 Impact factor: 10.057
Authors: Amira K Brown; Yasuyuki Kimura; Sami S Zoghbi; Fabrice G Siméon; Jeih-San Liow; William C Kreisl; Andrew Taku; Masahiro Fujita; Victor W Pike; Robert B Innis Journal: J Nucl Med Date: 2008-12 Impact factor: 10.057
Authors: Fabrice G Siméon; Jeih-San Liow; Yi Zhang; Jinsoo Hong; Robert L Gladding; Sami S Zoghbi; Robert B Innis; Victor W Pike Journal: Eur J Nucl Med Mol Imaging Date: 2012-08-11 Impact factor: 9.236
Authors: Talakad G Lohith; Tetsuya Tsujikawa; Fabrice G Siméon; Mattia Veronese; Sami S Zoghbi; Chul Hyoung Lyoo; Yasuyuki Kimura; Cheryl L Morse; Victor W Pike; Masahiro Fujita; Robert B Innis Journal: J Cereb Blood Flow Metab Date: 2016-01-01 Impact factor: 6.200